Shanghai Vitalgen BioPharma Co., Ltd. (hereinafter referred to as "Vitalgen") recently announced that VGN-R09b, its independently developed gene therapy product for the treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCD), has been granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA). This designation represents another significant milestone for VGN-R09b following its official inclusion in the Breakthrough Therapy Designation list in China, highlighting the product's global development potential in the AADCD treatment landscape.
Under relevant FDA policies, RPDD is designed to encourage the development of therapies for serious pediatric rare diseases. Receiving this designation not only signifies recognition of VGN-R09b's clinical potential for treating AADCD but also makes the product eligible to apply for a Priority Review Voucher (PRV) upon future approval in the United States. Successful acquisition of a PRV would help accelerate the development timeline of the company's overall product pipeline.
Dr. Zhao Xiaoping, CEO of the company, stated, "VGN-R09b receiving both Breakthrough Therapy Designation in China and RPDD from the U.S. FDA within a short period represents significant validation of the company's R&D strategy and global development approach. We will fully leverage the advantages provided by such regulatory policies to accelerate the global development of VGN-R09b, striving to bring this innovative therapy to children with AADCD worldwide as soon as possible."
About AADCD
AADCD is an autosomal recessive inherited neurometabolic disorder caused by pathogenic mutations in the DDC gene, leading to severe deficiencies in the synthesis of key neurotransmitters such as dopamine and serotonin. Affected infants present with severe motor dysfunction, autonomic nervous system disturbances, and intellectual developmental delay. Most fail to achieve motor developmental milestones such as head control, sitting independently, and walking. They face a high risk of mortality during infancy and early childhood, and their quality of life is severely impacted. Currently, there is no effective curative therapy for this disease in China. Conventional treatments can only partially alleviate symptoms and cannot repair the underlying neurological deficits, with particularly limited effects in severely affected patients.
About VGN-R09b
VGN-R09b utilizes a recombinant adeno-associated virus (rAAV) as a vector. Administered via a one-time intraparenchymal injection, it precisely delivers the therapeutic gene to the site of disease, enhancing dopamine synthesis in the brain while promoting neuroprotection, with the potential to achieve a fundamental treatment for the disease. VGN-R09b received approval from the National Medical Products Administration (NMPA) on April 19, 2024, to conduct clinical trials in China for Aromatic L-Amino Acid Decarboxylase Deficiency (AADCD) and Idiopathic Parkinson's Disease (PD), and the relevant registrational clinical studies are currently being actively advanced. Additionally, the product received approval from the U.S. Food and Drug Administration (FDA) on July 26, 2024, to conduct clinical studies for Idiopathic PD, and was granted Fast Track Designation (FTD) by the FDA on June 25, 2025.